Intravitreal Bevacizumab as Rescue Therapy in Persistent Central Serous Chorioretinopathy: A Case Report
This case report demonstrates that a single intravitreal bevacizumab injection successfully resolved persistent subretinal fluid and metamorphopsia in a patient with chronic central serous chorioretinopathy who failed medical therapy and was unsuitable for laser treatment, suggesting it as a viable rescue option for selected cases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine your eye is like a high-tech camera, and the back of it has a special sensor layer called the retina. Normally, this sensor sits flat and crisp, ready to take perfect pictures. But in a condition called Central Serous Chorioretinopathy (CSCR), a tiny leak develops in the "plumbing" behind the sensor. Think of it like a slow drip in a basement wall; water (fluid) starts pooling between the wall and the sensor, lifting it up and causing the picture to look wavy or blurry.
For most people, this leak stops on its own after a few weeks, like a puddle drying up in the sun. But for some, the leak keeps going, turning into a persistent puddle that won't dry. This is what happened to a 35-year-old woman in this story. She had been dealing with wavy vision in her left eye for three months.
First, the doctors tried the standard "dry-up" plan. They gave her a cocktail of medicines: pills to block certain hormones (eplerenone and acetazolamide) and eye drops (dorzolamide and nepafenac). They waited and watched for three months. But the puddle? It stayed. The water just wouldn't go away, even with all the help.
Next, the doctors looked for a way to patch the leak directly. They used a special camera (angiography) to find the exact spot where the water was escaping. They found a tiny leak right next to the center of her vision (the fovea). Usually, doctors can use a focused laser to cauterize a leak, like using a tiny soldering iron to seal a hole in a pipe. But here's the catch: the leak was so close to the center of her vision that using the laser would be like trying to fix a crack in a window while accidentally smashing the glass in the middle. It was too risky; it could have left her with a permanent blind spot right in the center of her sight. Laser was out. Another option, a therapy called Photodynamic Therapy (PDT), wasn't available at their hospital.
So, the team tried a different approach: a "rescue" shot. They injected a tiny amount of a medicine called bevacizumab (1.25 mg/0.05 mL) directly into the eye. Think of this medicine as a super-strong, targeted sponge that soaks up the signals telling the blood vessels to leak, helping the body reabsorb the fluid.
The result? It worked like magic, but the paper is careful to say it suggests this worked, not that it's a guaranteed cure for everyone. Just one week after the shot, the woman felt her vision straightening out. One month later, a scan showed the puddle was completely gone. The sensor was flat again, and her vision remained sharp at 20/20. No side effects popped up.
The authors are clear that this is just one story. They don't claim this is the new standard for everyone. They suggest that for the specific cases where the leak is too close to the center for a laser and other treatments have failed, this injection might be a useful "rescue" tool. It's a promising hint, but the paper insists we need more studies to be sure before we call it a solved problem. For now, it's a fascinating example of how doctors can think outside the box when the usual tools don't fit.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.